Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SDGR Stock Forecast 2025-2026
$21.22
Current Price
$1.54B
Market Cap
Buy 7
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to SDGR Price Targets
+83.8%
To High Target of $39.00
+50.8%
To Median Target of $32.00
+22.5%
To Low Target of $26.00
SDGR Price Momentum
-10.0%
1 Week Change
-18.8%
1 Month Change
-3.5%
1 Year Change
+10.0%
Year-to-Date Change
-25.5%
From 52W High of $28.47
+27.8%
From 52W Low of $16.60
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Schrodinger (SDGR) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on SDGR and similar high-potential opportunities.
Latest SDGR Stock Price Targets & Analyst Predictions
Based on our analysis of 15 Wall Street analysts, SDGR has a bullish consensus with a median price target of $32.00 (ranging from $26.00 to $39.00). The overall analyst rating is Strong Buy (8.9/10). Currently trading at $21.22, the median forecast implies a 50.8% upside. This outlook is supported by 7 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from David Lebowitz at Citigroup, projecting a 83.8% upside. Conversely, the most conservative target is provided by Chris Shibutani at Goldman Sachs, suggesting a 22.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SDGR Analyst Ratings
7
Buy
2
Hold
0
Sell
SDGR Price Target Range
Low
$26.00
Average
$32.00
High
$39.00
Current: $21.22
Latest SDGR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SDGR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 16, 2025 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $32.00 |
| Feb 27, 2025 | Piper Sandler | Joseph Catanzaro | Overweight | Maintains | $45.00 |
| Jan 24, 2025 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $27.00 |
| Nov 13, 2024 | BMO Capital | Gary Nachman | Outperform | Maintains | $28.00 |
| Oct 17, 2024 | BMO Capital | Gary Nachman | Outperform | Maintains | $25.00 |
| Aug 21, 2024 | Morgan Stanley | Vikram Malhorta | Equal-Weight | Maintains | $30.00 |
| Jul 11, 2024 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $25.00 |
| Jul 2, 2024 | Leerink Partners | Mani Foroohar | Outperform | Initiates | $29.00 |
| May 2, 2024 | Craig-Hallum | Matt Hewitt | Buy | Maintains | $30.00 |
| May 2, 2024 | Citigroup | David Lebowitz | Buy | Maintains | $37.00 |
| Mar 1, 2024 | Citigroup | David Lebowitz | Buy | Maintains | $39.00 |
| Mar 1, 2024 | Goldman Sachs | Chris Shibutani | Neutral | Maintains | $26.00 |
| Feb 29, 2024 | Piper Sandler | Joseph Catanzaro | Overweight | Maintains | $50.00 |
| Feb 29, 2024 | B of A Securities | Derik De Bruin | Neutral | Maintains | $32.00 |
| Feb 29, 2024 | Citigroup | David Lebowitz | Buy | Maintains | $39.00 |
| Feb 29, 2024 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $33.00 |
| Jan 26, 2024 | TD Cowen | Steven Mah | Outperform | Initiates | $42.00 |
| Jan 19, 2024 | Craig-Hallum | Matt Hewitt | Buy | Maintains | $35.00 |
| Dec 5, 2023 | Keybanc | Scott Schoenhaus | Overweight | Initiates | $38.00 |
| Nov 13, 2023 | Morgan Stanley | Vikram Malhorta | Equal-Weight | Maintains | $51.00 |
Schrodinger Inc. (SDGR) Competitors
The following stocks are similar to Schrodinger based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
SDGR
Schrodinger
mkt cap
1.71B
Schrodinger Inc. (SDGR) Financial Data
Schrodinger Inc. has a market capitalization of $1.54B with a P/E ratio of 44.4x. The company generates $230.49M in trailing twelve-month revenue with a -83.4% profit margin.
Revenue growth is +62.7% quarter-over-quarter, while maintaining an operating margin of -85.5% and return on equity of -43.3%.
Valuation Metrics
Market Cap
$1.54B
Enterprise Value
$1.12B
P/E Ratio
44.4x
PEG Ratio
-8.5x
Price/Sales
6.7x
Growth & Margins
Revenue Growth (YoY)
+62.7%
Gross Margin
+52.3%
Operating Margin
-85.5%
Net Margin
-83.4%
EPS Growth
+62.7%
Financial Health
Cash/Price Ratio
+32.1%
Current Ratio
3.5x
Debt/Equity
31.1x
ROE
-43.3%
ROA
-16.3%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Schrodinger Inc. (SDGR) Business Model
About Schrodinger Inc.
What They Do
Develops software for drug discovery and material design.
Business Model
The company generates revenue by offering advanced computational platforms and software solutions that aid in drug discovery and material design. Schrodinger's tools are utilized by a wide range of customers, including academic researchers and major pharmaceutical companies, allowing it to tap into diverse revenue streams across multiple industries.
Additional Information
Headquartered in New York City, Schrodinger is recognized for its proprietary physics-based computational technology, which significantly enhances the efficiency of scientific research and development processes. The company's innovative approach plays a crucial role in accelerating the journey from concept to market-ready products.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
891
CEO
Dr. Ramy Farid Ph.D.
Country
United States
IPO Year
2020
Website
www.schrodinger.comSchrodinger Inc. (SDGR) Latest News & Analysis
Latest News
Schrödinger Announces CFO Appointment
3 days ago
Quick Summary
Schrödinger (Nasdaq: SDGR) announced the departure of CFO Geoffrey Porges, who will be replaced by Richie Jain. Porges will remain as an advisor until June 6.
Why It Matters
Leadership changes can signal shifts in strategy or stability within a company. Investors may reassess Schrödinger's future performance and direction following the CFO transition.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Pomerantz LLP is investigating claims on behalf of Schrödinger, Inc. (NASDAQ:SDGR) investors. Interested parties should contact Danielle Peyton at the provided email or phone number.
Why It Matters
The investigation into Schrödinger could indicate potential legal issues or financial misconduct, raising concerns about the company's stability and affecting stock performance.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors who purchased Schrödinger, Inc. (NASDAQ:SDGR) securities. More info is available at bgandg.com/SDGR.
Why It Matters
The investigation into Schrödinger may indicate potential legal issues or financial discrepancies, which could impact the stock's value and investor confidence.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Schrödinger, Inc. (Nasdaq: SDGR) will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2025, at 1:25 p.m. E.T., with a webcast available on its website.
Why It Matters
Management's participation in a major healthcare conference could signal strategic developments and investor engagement, potentially influencing stock performance and market perception.
Source: Business Wire
Market Sentiment:
Neutral
Schrödinger: Regulatory Tailwinds Are Supportive Of Continued Strong Growth (Rating Upgrade)
3 days ago
Quick Summary
Schrödinger reported strong Q1 results with software growth and improving margins. FDA regulatory changes may benefit its predictive toxicity software, while Drug Discovery needs positive clinical data.
Why It Matters
Schrödinger's strong Q1 results and potential FDA regulatory shifts suggest growth in predictive software, impacting future profitability and market position, crucial for investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Schrödinger, Inc. (Nasdaq: SDGR) will present initial Phase 1 data for its MALT1 inhibitor SGR-1505 at two upcoming conferences in June 2025, focusing on safety evaluation.
Why It Matters
The announcement of initial Phase 1 clinical data for SGR-1505 highlights potential advancements in cancer treatment, impacting Schrödinger's valuation and investor sentiment in biotech.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About SDGR Stock
What is Schrodinger Inc.'s (SDGR) stock forecast for 2025?
Based on our analysis of 15 Wall Street analysts, Schrodinger Inc. (SDGR) has a median price target of $32.00. The highest price target is $39.00 and the lowest is $26.00.
Is SDGR stock a good investment in 2025?
According to current analyst ratings, SDGR has 7 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $21.22. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SDGR stock?
Wall Street analysts predict SDGR stock could reach $32.00 in the next 12 months. This represents a 50.8% increase from the current price of $21.22. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Schrodinger Inc.'s business model?
The company generates revenue by offering advanced computational platforms and software solutions that aid in drug discovery and material design. Schrodinger's tools are utilized by a wide range of customers, including academic researchers and major pharmaceutical companies, allowing it to tap into diverse revenue streams across multiple industries.
What is the highest forecasted price for SDGR Schrodinger Inc.?
The highest price target for SDGR is $39.00 from David Lebowitz at Citigroup, which represents a 83.8% increase from the current price of $21.22.
What is the lowest forecasted price for SDGR Schrodinger Inc.?
The lowest price target for SDGR is $26.00 from Chris Shibutani at Goldman Sachs, which represents a 22.5% increase from the current price of $21.22.
What is the overall SDGR consensus from analysts for Schrodinger Inc.?
The overall analyst consensus for SDGR is bullish. Out of 15 Wall Street analysts, 7 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $32.00.
How accurate are SDGR stock price projections?
Stock price projections, including those for Schrodinger Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 23, 2025 10:15 PM UTC